AKRO Overview
Upcoming Projects (AKRO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AKRO)
-
A second look: Discussing Rezdiffra and various investigational agents in MASH
Tickers: MDGL, AKRO, ETNB
Executed On: Oct 23, 2024 at 05:00 PM EDT -
Discussing various investigational agents in MASH and HBV
Tickers: MDGL, AKRO, ETNB
Executed On: Oct 15, 2024 at 11:00 AM EDT -
Looking into the Phase 2b HARMONY clinical trial results of efruxifermin (EFX) in patients with MASH.
Ticker: AKRO
Executed On: Mar 28, 2024 at 02:00 PM EDT -
A Second Look: Comparing 89bio's pegozafermin to Akero's efruxifermin in NASH
Tickers: ETNB, AKRO
Executed On: Mar 28, 2023 at 11:00 AM EDT -
Comparing 89bio's ENLIVEN data (pegozafermin) to Akero's efruxifermin in NASH
Tickers: ETNB, AKRO, MDGL, ICPT
Executed On: Mar 23, 2023 at 02:30 PM EDT -
Another view: A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 23, 2022 at 11:00 AM EST -
A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 18, 2022 at 03:00 PM EST -
Discussing the clinical landscape of NASH and the potential of Akero's Efruxifermin & Altimmunes Pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: AKRO, ALT
Executed On: Nov 01, 2022 at 10:30 AM EDT -
A Deep-Dive into Efruxifermin as a therapy for nonalcoholic steatohepatitis
Ticker: AKRO
Executed On: Sep 21, 2022 at 10:30 AM EDT
Upcoming & Overdue Catalysts (AKRO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AKRO)
-
Akero Therapeutics (AKRO) To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients At The Liver Meeting 2020
Ticker: AKRO
Occurred on: Nov 13, 2020
Strategic Initiatives (AKRO)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
